Standardized Data
Structured variables, controlled vocabularies, clinical metadata, and therapeutic characteristics support reusable analyses.
Open-access immunogenicity data
Immunogenicity Database Collaborative (IDC)
A grass-roots, cross-industry collaborative building an open-access database of immunogenicity data associated with biologic therapeutics.
IDC DS V1.00
Released
Therapeutic Molecules with Clinical Data
113
Clinical Trials
727
Patient Cohorts
1,788
Clinical Immunogenicity Readouts
4,146
Our Mission
Establish a shared database cataloging data associated with the immunogenicity of biotherapeutics.
By creating standardized and accessible datasets, the IDC seeks to accelerate scientific understanding of unwanted immunogenicity and improve immunogenicity risk assessment and mitigation strategies.
What is the IDC?
A scientific initiative and community resource
The IDC brings together scientists from industry, academia, and related organizations to harmonize fragmented immunogenicity information, enable new analyses, and provide a foundation for future community-driven data sharing.
Cross-Industry Collaboration
The collaborative reflects shared expertise across immunogenicity science, clinical development, data science, and related disciplines.
Open Access
The database is intended to serve researchers, developers, regulators, and data scientists as a sustainable public resource.
What We Have Accomplished
IDC DS V1
The first public IDC dataset release establishes the initial database architecture and clinical immunogenicity framework.
- Developed the initial IDC database architecture.
- Established a standardized framework for clinical immunogenicity data.
- Aggregated clinical immunogenicity observations and metadata.
- Compiled data covering 113 therapeutic molecules.
- Published a companion manuscript describing structure and analyses.
- Released the dataset to the scientific community.
Publication Status
BioRxiv preprint available. Companion manuscript currently under peer review.
Current Focus
IDC DB Expansion
The next phase expands clinical coverage, ADA impact data, and structures for nonclinical evidence.
Automated Clinical Data Expansion
Development of scalable data acquisition pipelines for ClinicalTrials.gov, the European Union Clinical Trials Registry, and additional public clinical data sources.
ADA Impact Data
Expansion beyond ADA frequency to capture pharmacokinetic, efficacy, safety, and neutralizing antibody outcomes.
Nonclinical Data Integration
Database structures for preclinical immunogenicity information, with an initial focus on in vitro T cell antigenicity readouts and future expansions into MAPPs, DC uptake, pre-existing ADA, biophysical properties, and other related data types.